Companies: 10,795·Total market cap: $144.5T
Monopar Therapeutics Inc.

Monopar Therapeutics Inc.

MNPRNASDAQHealthcare● Active
$60.61
+$1.13(+1.90%)
Market Cap$406030027
P/E Ratio
52W High$105
52W Low$29.18
Overview

Monopar Therapeutics Inc. (MNPR) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · MNPR · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-2.07mnpr eps ttm · mnpr earnings per shareEarnings history
PE Ratio (TTM)mnpr pe ratio ttm · mnpr price to earningsPE Ratio deep dive
Revenue (TTM)0.00mnpr revenue ttm · mnpr annual revenueFull revenue history
Dividend YieldNo Dividenddoes mnpr pay dividends · mnpr dividend yieldDividend history
Shares Outstanding7.4Mmnpr shares outstanding · mnpr floatShares outstanding history
Next EarningsAug 11, 2026Est.mnpr earnings date · mnpr next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
monopar therapeutics inc. revenue · mnpr revenue 2025
FY 2025Net Income-$13.7M▲ +11.99% YoY
202320242025
monopar therapeutics inc. net income · mnpr profit 2025
FY 2025EPS$-1.85▼ 36.03% YoY
202320242025
mnpr eps · monopar therapeutics inc. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$15.0MEPS: $-2.07View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy13 analystsis mnpr a buy · mnpr analyst rating
Strong Buy
0
Buy
11
Hold
2
Sell
0
Strong Sell
0
12-Month Price Target
$105.00Low
$60.61Current
$110.00Avg Target81.49% upside
$115.00High
mnpr price target · mnpr 12 month forecast

Total: 13 · Buy rate: 84.6%

The MNPR analyst consensus is Buy, based on ratings from 13 Wall Street analysts over the past 3 months. The average 12-month price target is $110.00, representing +81.49% upside from the current price of $60.61.

Stock Performance

Full History
1D+1.90%
1W+0.15%
1M-4.67%
3M+5.21%
YTD-7.18%
1Y+75.02%
5Y+108.64%

About Monopar Therapeutics Inc.

CEOChandler D. Robinson
IPO DateDec 19, 2019
Employees14
CountryUS

Monopar Therapeutics Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to pioneering novel cancer treatments within the United States. Its leading investigational drug, Val…

what is monopar therapeutics inc. · mnpr stock overview · monopar therapeutics inc. company profile · who is monopar therapeutics inc. ceo · mnpr NASDAQ · monopar therapeutics inc. headquarters · monopar therapeutics inc. business segments

About Stock Overview & Key Data

Monopar Therapeutics Inc. (MNPR) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Dec 19, 2019. As of the latest trading session, MNPR stock price is $60.61, with a market capitalization of $406.0M. The stock has returned +75.02% over the past 12 months and -7.18% year-to-date.

According to 13 Wall Street analysts, the consensus rating for Monopar Therapeutics Inc. stock is Buy, with an average 12-month price target of $110.00. In fiscal year 2025, Monopar Therapeutics Inc. reported revenue of — and net income of -$13.7M. For detailed data — including Monopar Therapeutics Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Monopar Therapeutics Inc. (MNPR) stock price is $60.61. The stock is traded on NASDAQ under the ticker symbol MNPR. The 52-week range is $29.18 – $105.00.

MNPR stock priceMNPR quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice